Home/AbbVie Inc.

AbbVie Inc.

ABBV · Health Care · Pharmaceuticals

Latest: Q3-2025
● NEUTRAL○ HYPE

This filing is a pre-earnings guidance update, not a full earnings call. AbbVie disclosed $2.7B in acquired IPR&D and milestones expense hitting Q3, which crushed adjusted EPS guidance down to $1.74-$1.78 for the quarter. Full-year adjusted EPS guided to $10.38-$10.58.

Revenue: —Evasion: 0%0
Earnings History
Q3-2025Q3 FY2025○ HYPE

This filing is a pre-earnings guidance update, not a full earnings call. AbbVie disclosed $2.7B in acquired IPR&D and milestones expense hitting Q3, which crushed adjusted EPS guidance down to $1.74-$1.78 for the quarter. Full-year adjusted EPS guided to $10.38-$10.58.

● NEUTRAL